These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23221565)

  • 41. Characteristics of Artificial Immunogens Containing Peptide Mimotopes of HIV-1 Epitopes Recognized by Monoclonal Antibodies 2F5 and 2G12.
    Shcherbakova NS; Chikaev AN; Rudometov AP; Shcherbakov DN; Il'ichev AA; Karpenko LI
    Bull Exp Biol Med; 2019 Jun; 167(2):259-262. PubMed ID: 31243678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.
    Raman SC; Mejías-Pérez E; Gomez CE; García-Arriaza J; Perdiguero B; Vijayan A; Pérez-Ruiz M; Cuervo A; Santiago C; Sorzano COS; Sánchez-Corzo C; Moog C; Burger JA; Schorcht A; Sanders RW; Carrascosa JL; Esteban M
    Front Immunol; 2019; 10():2793. PubMed ID: 31867001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
    J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.
    Xiao X; Chen W; Feng Y; Zhu Z; Prabakaran P; Wang Y; Zhang MY; Longo NS; Dimitrov DS
    Biochem Biophys Res Commun; 2009 Dec; 390(3):404-9. PubMed ID: 19748484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody responses to the HIV-1 envelope high mannose patch.
    Daniels CN; Saunders KO
    Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.
    Moody MA; Yates NL; Amos JD; Drinker MS; Eudailey JA; Gurley TC; Marshall DJ; Whitesides JF; Chen X; Foulger A; Yu JS; Zhang R; Meyerhoff RR; Parks R; Scull JC; Wang L; Vandergrift NA; Pickeral J; Pollara J; Kelsoe G; Alam SM; Ferrari G; Montefiori DC; Voss G; Liao HX; Tomaras GD; Haynes BF
    J Virol; 2012 Jul; 86(14):7496-507. PubMed ID: 22553329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assembling different antennas of the gp120 high mannose-type glycans on gold nanoparticles provides superior binding to the anti-HIV antibody 2G12 than the individual antennas.
    Chiodo F; Enríquez-Navas PM; Angulo J; Marradi M; Penadés S
    Carbohydr Res; 2015 Mar; 405():102-9. PubMed ID: 25573666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design.
    Clark BE; Auyeung K; Fregolino E; Parrilli M; Lanzetta R; De Castro C; Pantophlet R
    Chem Biol; 2012 Feb; 19(2):254-63. PubMed ID: 22365608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.
    Joyce JG; Krauss IJ; Song HC; Opalka DW; Grimm KM; Nahas DD; Esser MT; Hrin R; Feng M; Dudkin VY; Chastain M; Shiver JW; Danishefsky SJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15684-9. PubMed ID: 18838688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.
    Sanders RW; van Anken E; Nabatov AA; Liscaljet IM; Bontjer I; Eggink D; Melchers M; Busser E; Dankers MM; Groot F; Braakman I; Berkhout B; Paxton WA
    Retrovirology; 2008 Jan; 5():10. PubMed ID: 18237398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
    Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A solution NMR study of the interactions of oligomannosides and the anti-HIV-1 2G12 antibody reveals distinct binding modes for branched ligands.
    Enríquez-Navas PM; Marradi M; Padro D; Angulo J; Penadés S
    Chemistry; 2011 Feb; 17(5):1547-60. PubMed ID: 21268157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy.
    Murin CD; Julien JP; Sok D; Stanfield RL; Khayat R; Cupo A; Moore JP; Burton DR; Wilson IA; Ward AB
    J Virol; 2014 Sep; 88(17):10177-88. PubMed ID: 24965454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.
    Yacoob C; Lange MD; Cohen K; Lathia K; Feng J; Glenn J; Carbonetti S; Oliver B; Vigdorovich V; Sather DN; Stamatatos L
    PLoS Pathog; 2018 Jun; 14(6):e1007120. PubMed ID: 29933399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity.
    Doores KJ; Fulton Z; Hong V; Patel MK; Scanlan CN; Wormald MR; Finn MG; Burton DR; Wilson IA; Davis BG
    Proc Natl Acad Sci U S A; 2010 Oct; 107(40):17107-12. PubMed ID: 20852065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.